Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery

2003 ◽  
Vol 4 (4) ◽  
pp. 444-446 ◽  
Author(s):  
Leah Leibovitch ◽  
Gili Kenet ◽  
Kineret Mazor ◽  
Ilan Matok ◽  
Amir Vardi ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Pulmonary Hemorrhage ◽  
Pediatric Cardiac Surgery ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Life Threatening

Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery

2012 ◽  
Vol 20 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Sarvesh Pal Singh ◽  
Sandeep Chauhan ◽  
Minati Choudhary ◽  
Sumit Vasdev ◽  
Sachin Talwar
Keyword(s):  
Cardiac Surgery ◽  
Pediatric Cardiac Surgery ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii

Defining the role of recombinant activated factor VII in pediatric cardiac surgery: Where should we go from here?*

2009 ◽  
Vol 10 (5) ◽  
pp. 572-582 ◽  
Author(s):  
Oliver J. Warren ◽  
Paula L. B. Rogers ◽  
Amy L. Watret ◽  
Katie L. de Wit ◽  
Ara W. Darzi ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Pediatric Cardiac Surgery ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii

The Use of Recombinant Activated Factor VII in Australia and New Zealand.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4025-4025
Author(s):  
Scott Dunkley ◽  
Peter A. Cameron ◽  
Louise E. Phillips ◽  
James Isbister
Keyword(s):  
Cardiac Surgery ◽  
New Zealand ◽  
Adverse Events ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Safety And Efficacy ◽  
Activated Factor Vii ◽  
Wide Range ◽  
Life Threatening ◽  
New Treatments

Abstract Introduction: The role of Recombinant activated factor VII (rFVIIa, NovoSeven) for off-label indications, including trauma, cardiac surgery and other critical bleeding episodes, remains controversial. Through the Haemostasis Registry, we report on the Australian and New Zealand experience of using rFVIIa. Methods: Monash University has established the Haemostasis Registry (with an educational grant from NovoNordisk Pharmaceuticals) to monitor the use of rFVIIa throughout Australia and New Zealand. More than 50 hospitals are contributing data to the Registry. Results: Over 600 cases have been reported to the Register. In those where complete data has been received, major areas of use are cardiac surgery (~42%), other surgery (~19%) and trauma (~13%). The reported efficacy of rFVIIa was high (where reported, in >70% cases bleeding decreased or stopped after first dose of rFVIIa) while the reported Adverse Events “possibly” or “probably” linked to rFVIIa use were relatively low (~6%). There were no directly linked adverse events. Despite suffering from conditions where mortality is high, the survival rate in rFVIIa recipients was 69% at 28 days post treatment. These results will be compared with international experience and published trials. Conclusions: Although randomized controlled trials are important in establishing the safety and efficacy of new treatments, they do not replace the need for registries, especially for treatments where clinicians believe that withholding treatment may be unethical because of potential life threatening consequences. This problem is made more difficult where there are a wide range of applications. As more data becomes available, the Haemostasis Registry data will help to elucidate the safety and efficacy of rFVIIa and provide important feedback to doctors and hospitals.

Recombinant Activated Factor VII Administration after Pulmonary Embolectomy: Case Report

2013 ◽  
Vol 16 (4) ◽  
pp. 205
Author(s):  
Nedal Omran ◽  
Jan Harrer ◽  
Miroslav Brtko ◽  
Petr Habal ◽  
Zdenek Turek ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Case Report ◽  
Thromboembolic Event ◽  
Factor Vii ◽  
Coagulation Disorder ◽  
Recombinant Activated Factor Vii ◽  
Pulmonary Embolectomy ◽  
Bleeding Management ◽  
Activated Factor Vii ◽  
Life Threatening

Bleeding management in cardiac surgery could be a great challenge for the surgeon and a life-threatening moment for the patient. Despite the fact that recombinant activated factor VII is now widely accepted as a useful adjunct in the management of postcardiotomy coagulopathy, its use in the course of recent thromboembolic event is rarely described. We hereby present a case of rescue recombinant activated factor VII administration to manage a severe coagulation disorder during surgical pulmonary embolectomy performed under cardiopulmonary bypass.

Sign in / Sign up

Export Citation Format

Share Document